Loozfibre

Quick links to important sections

Loozfibre

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loozfibre

Quick Facts

Property Description
Active Ingredients Ispaghula Husk, Lactitol Monohydrate
Form Granules or Powder for solution
Pharmacological Class Laxatives (Bulk-forming and Osmotic combination)
General Purpose To support and regulate intestinal function
Origin Natural derivative (Ispaghula) and Synthetic derivative (Lactitol)

1. What is Loozfibre and How is it Classified?

Loozfibre is a dual-action combination medication classified under the high-level therapeutic category of Laxatives, used in the general management of bowel function. This preparation is defined by its strategic inclusion of two distinct active ingredients, Ispaghula and Lactitol, which provide a comprehensive strategy for intestinal support. The combination is recognized for providing a dual mechanism, distinguishing it from single-agent laxatives.

Lactitol functions as an osmotic agent to treat chronic constipation. This means the medicine helps by gently drawing water into the bowel to soften the contents and promote easier passage.

2. Composition and Pharmaceutical Form of Loozfibre

The formulation features two key active ingredients: Ispaghula husk and Lactitol Monohydrate, which are supplied as granules or a powder for solution intended for oral administration. Ispaghula, the natural derivative component, is sourced from the Plantago ovata seed. Conversely, Lactitol is the synthetic derivative, a non-absorbable sugar alcohol that functions as an osmotic agent.

Ispaghula, as a soluble fiber, contributes to the overall management of bowel function through its volume-enhancing properties. This substance acts to increase stool mass and moisture, while Lactitol ensures the contents are adequately hydrated. The unique combination and granular form require mixing with an aqueous vehicle prior to ingestion.

3. Understanding Loozfibre's Dual-Action Approach

Loozfibre’s approach is defined by its synergistic action, combining the physical effect of bulk-forming with the chemical principle of osmotic effect. The bulk-forming action ensures that the intestinal contents are voluminous, while the osmotic effect ensures the contents are adequately hydrated. By optimizing both factors simultaneously, the dual-action method is designed to provide effective and regulated support, leading to a smoother process for comfortable elimination.

What side effects are possible with Loozfibre?

Possible Side Effects and Safety Information

The safety profile for Loozfibre, a dual-component laxative, is primarily characterized by effects related to the gastrointestinal system, as documented in official regulatory labeling. These adverse reactions are categorized by frequency based on clinical and post-marketing data.

Classification Representative Adverse Reactions
Common Flatulence, abdominal distension, abdominal pain, and diarrhea are frequently documented, reflecting the actions of the osmotic and bulk-forming components. Other common effects include upper respiratory tract infection.
Not Known Hypersensitivity reactions, including rash, urticaria, and severe reactions such as anaphylaxis, are documented but classified as frequency Not Known based on available regulatory data.

Flatulence and abdominal distension are often observed at the start of treatment but are typically noted in official sources to diminish with continued regular use. Conversely, prolonged exposure or chronic misuse of high doses can be associated with disturbances in the electrolyte balance.

Serious adverse reactions are explicitly noted in regulatory documents. These include the documented risks of intestinal or esophageal obstruction linked to the bulk-forming component (Ispaghula Husk) if consumed with insufficient fluid. Furthermore, the risk of anaphylaxis is cited as a serious systemic safety concern. Official labeling restricts the use of Loozfibre in patients with existing gastrointestinal obstructions, faecal impaction, or the metabolic condition galactosaemia. Medical supervision for long-term use is advised for older or debilitated patients.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section outlines the officially documented manifestations and required actions in the event of an overdose of Loozfibre, based strictly on government regulatory labeling for its active components, Ispaghula husk and Lactitol monohydrate.

Overdose is primarily associated with severe gastrointestinal effects, which are an extension of the known laxative action.

Documented Manifestations and Complications

Overdose Presentation Severe Outcome/Risk
Abdominal discomfort, pain, and flatulence Fluid and Electrolyte Imbalance (Risk of hypopotassemia)
Severe diarrhea Dehydration from prolonged loss of liquids
Acute Choking/Obstruction (If taken with inadequate fluid) Blockage of the throat, esophagus, or intestine

Required Emergency Actions

The primary official instruction is to seek immediate medical help or contact a Poison Control Center right away upon suspected overdose. Urgent medical attention is explicitly required if symptoms of a blockage occur, such as difficulty swallowing or breathing, chest pain, or vomiting, after ingesting the bulk-forming component.

Antidote and Supportive Measures: No specific antidote is documented in regulatory labeling. Overdose management is symptomatic and supportive. Instructions mandate that any significant loss of liquids and electrolytes resulting from diarrhea must be replaced under medical guidance.

Therapeutic Uses of Loozfibre

What Loozfibre Treats: Main Uses and Benefits

Loozfibre is commonly used to help with the management of Chronic Idiopathic Constipation (CIC), applied in situations where patients experience persistent, difficult, and infrequent bowel movements. The medication is considered relevant when supportive symptomatic management is appropriate for symptoms that become more disruptive during flare-ups, and generally may assist with maintaining a sense of stability and regularity in intestinal function. The components of this formulation are used for the treatment of habitual constipation and in situations where softening the stools is desirable.

Applied across therapeutic domains where additional symptomatic support is needed, the combination generally supports symptomatic relief for symptoms related to physical discomfort, such as hard, dry stools and excessive straining. The supportive medication may contribute to improved comfort during periods of symptomatic discomfort and assist with maintaining functional stability. The benefit supports patients whose medical status requires the avoidance of strenuous physical effort by assisting with comfortable stool passage and easing physical strain. The dual-component approach is used for conditions such as chronic constipation, haemorrhoids, and anal fissures, as well as for supportive care during postoperative recovery.


Quick Fact: Relief for Straining and Hard Stools The dual-component approach is used to manage the physical symptoms of difficult evacuation, helping to ease the physical effort needed for a bowel movement.

Regulatory References

  1. European Medicines Agency's conclusions on ispaghula husk

Eligibility and Restrictions for Use

Official Population Eligibility for Loozfibre

Loozfibre (Ispaghula Husk and Lactitol Monohydrate) is generally intended for use by adults. Official regulatory labeling defines strict population boundaries regarding who can and cannot use this medicine.

Absolute Contraindications

Use is contraindicated and explicitly prohibited in patients with pre-existing conditions that include known or suspected gastrointestinal obstruction, faecal impaction, or undiagnosed acute abdominal pain. Due to the composition of the Lactitol component, the medicine is also absolutely contraindicated in individuals diagnosed with galactosemia or known hypersensitivity to any of the formulation's ingredients.

Age and Physiological Restrictions

Loozfibre is not recommended for use in children and adolescents, as safety and effectiveness are not established in pediatric groups under the regulated minimum age (typically 12 or 18 years). Use during pregnancy or while breastfeeding is restricted and should only occur following professional consultation, with the medicine used only if the potential benefit is determined to outweigh the potential risk.

Conditional Use and Regulatory Caution

Patients with Diabetes Mellitus should use Loozfibre with caution, as regulatory documents advise that the Lactitol component may affect blood glucose levels. Caution is also advised when the medicine is used in patients with impaired renal function, or in elderly and debilitated patients where supervision of treatment may be advisable.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Loozfibre, a non-systemically absorbed drug (such as a bulk-forming agent or osmotic laxative), primarily involves physical interference with absorption and additive pharmacodynamic effects.

Interaction Constraints and Timing

To minimize the risk of reduced systemic absorption of co-administered medicines, it is officially documented that Loozfibre should not be taken within two hours before or after any other oral medicinal products. This timing separation applies broadly to all orally administered drugs, including cardiac glycosides, minerals, and vitamins.

Pharmacodynamic and Absorption Interactions

Category of Interaction Affected Products or Mechanism Regulatory Requirement
Absorption Interference All co-administered oral medications (e.g., Digoxin, Carbamazepine, Vitamins) Mandatory 2-hour separation of doses
Electrolyte Balance Diuretics (e.g., Thiazides) or Corticosteroids Increased monitoring for potassium loss
Anticoagulation Coumarin derivatives (e.g., Warfarin) Increased monitoring due to potential additive effect
Other Laxatives Any concurrent laxative or purgative Do not combine without medical supervision

Population-Specific Notes

For patients on long-term treatments like thyroid hormones or antidiabetic agents, dose adjustments may be necessary due to the potential for Loozfibre to affect their absorption or metabolic control. Elderly or debilitated patients on chronic use may require regular monitoring of serum electrolyte levels.

Mechanism of Action

Dual Mechanism: Luminal Fluid Dynamics and Bulk Formation

This domain addresses the drug’s non-systemic, local action on the contents of the colon. The mechanism involves the osmotic power of Lactitol, which increases solute concentration in the intestinal lumen, and the hydrophilic absorption of Ispaghula husk to bind that fluid, resulting in contents that are both voluminous and highly hydrated. This action alters the physical properties of the colonic contents and contributes to the mechanical stimulus for motility.

Neuro-Muscular Reflex Activation

The contents, having been significantly increased in volume and hydration, initiate this second stage of the mechanism by physically distending the colonic wall. This stretch activates mechanoreceptors linked to the Enteric Nervous System (ENS), thereby initiating an increase in peristaltic contractions and propulsive movement. This activation is chemically supported by short-chain fatty acids produced from Lactitol, which further modulate smooth muscle activity.

Synergy and Physiological Modulation

This dual mechanism addresses both the requirement for volume needed for reflex activation and the need for optimal fluidity within the colonic contents. This synergistic approach modulates the lower GI tract's motility and fluid balance through the co-ordinated physical and osmotic mechanisms.

Dosage and Administration Information

Loozfibre is administered solely through the oral route as a solution prepared from its granules or powder form. The entire dose should be fully dissolved in a set volume of liquid, typically 4 to 8 ounces of water, juice, or another compatible beverage, and ingested immediately after mixing.

The standard adult dosing regimen is based on a once-daily schedule. The initial dose for treatment is typically 20 g of the Lactitol component equivalent. A key instruction relating to proper use is the necessary dose adjustment: if a patient experiences persistent loose stools during treatment, the daily dose must be reduced to 10 g. The dose is taken with meals or immediately following them.

The overall administration protocol includes specific timing constraints to ensure proper procedural use. The compound must be separated from any other concurrently taken oral medications by an interval of at least two hours to prevent altered absorption. Furthermore, due to the presence of the bulk-forming agent, Loozfibre must not be taken immediately before going to sleep. Safety and effectiveness guidelines have not been established for use in pediatric patients.

Note that the initial response typically requires 24 to 48 hours, and users must maintain adequate fluid intake throughout the day to support the bulk-forming component.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Loozfibre


Evidence for Use in Chronic Idiopathic Constipation (CIC)

The evidence base for Loozfibre, a combination of Ispaghula and Lactitol, draws significantly from numerous short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews conducted for each active component individually. These studies were designed to explore how symptoms change over time in adults diagnosed with Chronic Idiopathic Constipation. Researchers monitored outcomes such as changes in weekly bowel movement frequency and objective measures of stool consistency.

Research highlights changes measured during the study period, where findings describe patterns observed in trials comparing the single components against placebo or other common osmotic or bulk-forming agents. In these short-term studies, research describes patterns in data related to stool frequency and consistency measured for the individual ingredients. However, the evidence is characterized by variability (heterogeneity) in how trials were conducted, including differences in dosing and patient selection criteria.

Regarding the specific combination product, there is limited dedicated research available to directly compare the dual-agent combination against its individual components or placebo; thus, the specific actions of the combination require further investigation.


Research in Conditions Requiring Soft Stool

The components of Loozfibre were evaluated in research contexts involving conditions where symptoms may vary in intensity, such as haemorrhoids and anal fissures, and in supportive care during postoperative recovery. The research explored outcomes in contexts where stool softening is sought. Studies monitored patient-reported outcomes describing perceived physical discomfort and straining during bowel movements, alongside measures of stool consistency.


What Is Still Uncertain About Loozfibre Research

Research provides context but not individual predictions, and the available evidence highlights what is known and what is still uncertain. The primary uncertainty lies in the lack of large-scale, comparative RCTs dedicated to the specific dual-agent combination. The extent to which the combination provides specific, measurable properties that differ from using the individual components alone is not fully established.

Key research limitation frames include the short duration of most controlled trials, meaning long-term effects are not fully established. Additionally, consistency of the evidence varies across studies due to differing methodologies and patient inclusion criteria.

Frequently Asked Questions (FAQ)

Common questions about Loozfibre (FAQ)

Q: Is Loozfibre the same as the fiber you get from food?

Official product information describes Loozfibre as a dual-action medicine containing two active ingredients. One component, Ispaghula (psyllium husk), is a natural fiber derivative. The other component, Lactitol, is a synthetic agent that uses osmosis to draw water into the bowel. This combination provides a unique mechanism compared to simply increasing dietary fiber intake.

Q: What are the main conditions Loozfibre is officially approved for?

Regulatory documents indicate that Loozfibre is approved for treating Chronic Constipation, also known as Chronic Idiopathic Constipation (CIC). Additionally, the components of the medicine have been studied and used to support conditions where the passage of a soft stool is needed, such as with haemorrhoids or anal fissures.

Q: Is Loozfibre different from other prescription treatments for the same condition?

The official classification for Loozfibre highlights its dual approach. It is categorized as a combination laxative because it strategically includes both a bulk-forming agent and an osmotic agent. This dual mechanism is what distinguishes it from prescription treatments that rely on only one method of action.

Q: Can Loozfibre interact with common over-the-counter pain relievers?

Official instructions describe the need for a time separation between Loozfibre and any other oral medicinal products. This is done to prevent the bulk-forming agent from interfering with the absorption of other pills. Therefore, the administration protocol requires that all orally taken medications, including common over-the-counter pain relievers, be separated by at least two hours.

Q: Is it possible for Loozfibre to interact with certain herbal teas?

Product information notes that Loozfibre is to be taken at least two hours apart from any other oral medicinal products. If an herbal tea is being taken as a medicinal remedy or supplement, the product information indicates that the two-hour separation interval applies.

Q: What is the difference between Loozfibre and generic fiber supplements?

Loozfibre is regulated as a dual-action prescription laxative. It is distinguished from generic fiber supplements because it combines two methods: the bulk-forming action of Ispaghula and the osmotic action of Lactitol. Many generic supplements are single-agent products that only provide bulk-forming fiber.

Q: Are the side effects of Loozfibre temporary or long-lasting?

Official product documentation notes that gastrointestinal side effects, such as flatulence and abdominal distension, are frequently observed when starting the treatment. These common effects are generally mild and are noted to diminish with continued regular use of the medication.

Q: Can Loozfibre be taken if I am already taking an antidepressant?

The official administration protocol notes that a two-hour time separation is required between Loozfibre and all other oral medications, including prescription drugs like antidepressants. This measure is taken to minimize the risk of the bulk-forming agent reducing the absorption of other medicines.

Q: Is Loozfibre safe for individuals with a history of heart issues?

The official product information advises caution and special monitoring for patients taking certain heart-related medications, such as cardiac glycosides, or those taking diuretics. These warnings relate to the potential for Loozfibre to affect electrolyte balance. The medicine is intended for use following a comprehensive review of a patient's medical history by a prescribing professional.

Q: Is Loozfibre known to interact with birth control pills?

As an oral medicinal product, the administration protocol requires birth control pills to be separated from Loozfibre by a minimum of two hours. Official documents emphasize this timing separation to ensure that the bulk-forming agent does not interfere with the absorption of co-administered oral medicines.

Q: How long can a person expect to need to use Loozfibre?

Official information indicates that Loozfibre is generally intended for daily use to help maintain regular intestinal function. However, regulatory guidelines advise that prolonged usage beyond a short-term period is generally reviewed by a healthcare professional.

Q: Are there any foods or drinks that should be avoided while using Loozfibre?

To minimize common side effects like flatulence and abdominal discomfort, regulatory guidance suggests that reducing intake of foods or drinks known to produce excess gas may help minimize these common side effects. Examples often include carbonated beverages and certain gas-producing vegetables.

Q: Does Loozfibre have a risk of becoming habit-forming?

Official sources state that the combination of Ispaghula and Lactitol has not demonstrated habit-forming tendencies. However, as is the case with all laxatives, product information includes a warning against prolonged abuse, which may lead to dependence on the use of a laxative for a bowel movement.

Q: Why do some people say Loozfibre made them feel nauseous?

Official documents that list possible adverse reactions include nausea and vomiting. These are generally categorized as less common effects that have been reported from the Lactitol component of the medicine.

Q: Is there a generic version of Loozfibre available?

The combination of active ingredients in Loozfibre, Ispaghula Husk and Lactitol Monohydrate, is available from several manufacturers under different product names. Information regarding the specific availability of a product containing this combination can be found by contacting a pharmacist.

Q: Does Loozfibre have any official warnings about driving or operating machinery?

Official product information states that Loozfibre has no or negligible influence on a person's ability to drive or use machinery. However, if an individual experiences any side effects that could potentially impair their abilities, such as dizziness, official warnings state that in such a situation, activities requiring attention should be avoided.

Q: If I miss a dose of Loozfibre, what are the general guidelines mentioned?

Official product information contains general guidelines for a missed dose, which state that if the time for the next dose is near, the missed dose is to be skipped. The guidelines further note that the dose should not be doubled to compensate for the missed administration.

Q: What kind of medical professionals typically prescribe Loozfibre?

Loozfibre is available only by prescription from a qualified medical professional, such as a General Practitioner. Regulatory context indicates that these products are often managed or recommended by specialists like Gastroenterologists.

How should Loozfibre be stored and disposed of?

How to Store and Dispose of Loozfibre

Loozfibre (Ispaghula Husk and Lactitol Monohydrate) must be stored strictly according to regulatory labeling to maintain its stability.

Storage Requirement Official Condition
Temperature Store below 30 C (86 F); Do not freeze.
Protection Keep in the original container, tightly closed, protected from light and moisture.
Prepared Product The mixture (powder/granules in liquid) must be consumed immediately; do not store the solution.
Safety Keep out of the sight and reach of children at all times.

Unused or expired Loozfibre must be handled as pharmaceutical waste. Disposal must be carried out according to local regulatory guidelines, which often require consultation with a pharmacist or collection point and prohibit discarding the product into drains or sewer systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Loozfibre found in:

A-Z Index: